Grace Therapeutics, Inc
GRCE3.400USD
+0.050+1.49%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
48.04MMarket Cap
LossP/E TTM
More Details of Grace Therapeutics, Inc Company
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Grace Therapeutics, Inc Info
Ticker SymbolGRCE
Company nameGrace Therapeutics, Inc
IPO dateMar 07, 2013
CEOKohli (Prashant)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 07
Address103 Carnegie Center
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16093221602
Websitehttps://www.gracetx.com/
Ticker SymbolGRCE
IPO dateMar 07, 2013
CEOKohli (Prashant)
Company Executives of Grace Therapeutics, Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
Mr. Robert J. Delaversano
Mr. Robert J. Delaversano
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Dr. R. Loch Macdonald, M.D., Ph.D.
Dr. R. Loch Macdonald, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. S. George Kottayil
Dr. S. George Kottayil
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
Revenue Breakdown
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Canada
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shore Pharma LLC
8.63%
Nantahala Capital Management, LLC
7.61%
SS Pharma LLC
6.97%
Rajitha Grace 2018 Irrevocable Trust
5.05%
AIGH Capital Management, LLC.
4.33%
Other
67.40%
Shareholders
Shareholders
Proportion
Shore Pharma LLC
8.63%
Nantahala Capital Management, LLC
7.61%
SS Pharma LLC
6.97%
Rajitha Grace 2018 Irrevocable Trust
5.05%
AIGH Capital Management, LLC.
4.33%
Other
67.40%
Shareholder Types
Shareholders
Proportion
Corporation
20.65%
Hedge Fund
10.61%
Individual Investor
6.41%
Private Equity
4.33%
Research Firm
3.23%
Investment Advisor/Hedge Fund
2.93%
Investment Advisor
2.87%
Bank and Trust
0.02%
Other
48.95%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
3.65M
26.41%
-505.40K
2025Q2
46
7.78M
66.51%
+1.05M
2025Q1
48
7.92M
57.31%
+1.83M
2024Q4
47
5.99M
59.05%
-359.46K
2024Q3
42
6.02M
59.34%
-98.00K
2024Q2
44
6.05M
59.66%
+810.14K
2024Q1
42
2.77M
33.70%
+1.44M
2023Q4
43
2.08M
26.30%
+647.61K
2023Q3
42
2.06M
26.16%
+1.15M
2023Q2
48
913.80K
16.66%
+138.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shore Pharma LLC
1.34M
9.66%
+147.28K
+12.40%
Jul 18, 2025
Nantahala Capital Management, LLC
1.18M
8.52%
--
--
Jun 30, 2025
SS Pharma LLC
1.08M
7.8%
+147.28K
+15.81%
Jul 18, 2025
Rajitha Grace 2018 Irrevocable Trust
781.59K
5.65%
--
--
Jul 18, 2025
AIGH Capital Management, LLC.
840.08K
6.07%
-143.10K
-14.55%
Jun 30, 2025
BofA Global Research (US)
494.70K
3.58%
--
--
Jun 30, 2025
Kottayil (George)
494.70K
3.58%
--
--
Jul 18, 2025
Kavuru (Vimal)
426.32K
3.08%
--
--
Jul 18, 2025
The Vanguard Group, Inc.
409.10K
2.96%
+153.70K
+60.18%
Jun 30, 2025
Adar1 Capital Management LLC
176.63K
1.28%
-166.88K
-48.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Unusual Whales Subversive Republican Trading ETF
0%
Unusual Whales Subversive Republican Trading ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
Date
Type
Ratio
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
FAQs
Who are the top five shareholders of Grace Therapeutics, Inc?
The top five shareholders of Grace Therapeutics, Inc are:
Shore Pharma LLC holds 1.34M shares, accounting for 9.66% of the total shares.
Nantahala Capital Management, LLC holds 1.18M shares, accounting for 8.52% of the total shares.
SS Pharma LLC holds 1.08M shares, accounting for 7.80% of the total shares.
Rajitha Grace 2018 Irrevocable Trust holds 781.59K shares, accounting for 5.65% of the total shares.
AIGH Capital Management, LLC. holds 840.08K shares, accounting for 6.07% of the total shares.
Shore Pharma LLC holds 1.34M shares, accounting for 9.66% of the total shares.
Nantahala Capital Management, LLC holds 1.18M shares, accounting for 8.52% of the total shares.
SS Pharma LLC holds 1.08M shares, accounting for 7.80% of the total shares.
Rajitha Grace 2018 Irrevocable Trust holds 781.59K shares, accounting for 5.65% of the total shares.
AIGH Capital Management, LLC. holds 840.08K shares, accounting for 6.07% of the total shares.
What are the top three shareholder types of Grace Therapeutics, Inc?
The top three shareholder types of Grace Therapeutics, Inc are:
Shore Pharma LLC
Nantahala Capital Management, LLC
SS Pharma LLC
Shore Pharma LLC
Nantahala Capital Management, LLC
SS Pharma LLC
How many institutions hold shares of Grace Therapeutics, Inc (GRCE)?
As of 2025Q3, 40 institutions hold shares of Grace Therapeutics, Inc, with a combined market value of approximately 3.65M, accounting for 26.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -40.10%.
What is the biggest source of revenue for Grace Therapeutics, Inc?
In FY2021, the -- business generated the highest revenue for Grace Therapeutics, Inc, amounting to -- and accounting for --% of total revenue.
